A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Endometrial Carcinosarcoma Clinical Trial

Official title:
A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers

Status Recruiting

Clinical Trial Summary

The purpose of this study is to find out whether the combination of pembrolizumab and olaparib is an effective treatment for people with persistent or recurrent endometrial cancer or endometrial carcinosarcoma. The researchers will also look at the safety of the drug combination and whether it causes few or mild side effects in participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05156268
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Maria Rubinstein, MD
Phone	646-888-6954
Email	rubinstm@mskcc.org
Status	Recruiting
Phase	Phase 2
Start date	January 27, 2022
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04106414` - Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment	Phase 2
Recruiting	`NCT05001282` - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	Phase 1/Phase 2
Active, not recruiting	`NCT03651206` - Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib	Phase 2/Phase 3
Completed	`NCT03015129` - A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer	Phase 2